<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006014</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02351</org_study_id>
    <secondary_id>UCCRC-10409</secondary_id>
    <secondary_id>UCCRC-NCI-44</secondary_id>
    <secondary_id>NCI-44</secondary_id>
    <secondary_id>CDR0000068023</secondary_id>
    <nct_id>NCT00006014</nct_id>
  </id_info>
  <brief_title>SU5416 in Treating Patients With Malignant Mesothelioma</brief_title>
  <official_title>A Phase II Trial of SU5416 (NSC# 696819) in Patients With Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant&#xD;
      mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to&#xD;
      the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate, median and overall survival, and time to&#xD;
      progression in patients with unresectable malignant mesothelioma treated with SU5416.&#xD;
&#xD;
      II. Determine the effect of SU5416 on surrogate biologic endpoints, including microvessel&#xD;
      density, tissue proliferative index, apoptosis, vascular endothelial growth factor levels,&#xD;
      and tumor perfusion measured by MRI in these patients.&#xD;
&#xD;
      III. Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a&#xD;
      minimum of 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 21-45 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaxanib</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven malignant mesothelioma (epithelial,&#xD;
             sarcomatoid, or mixed subtype) that is not amenable to surgery or radiotherapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  At least 20 mm by conventional techniques or at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  Pleural effusions and ascites are not considered measurable lesions&#xD;
&#xD;
          -  Only site of measurable disease must not be located within prior radiotherapy port&#xD;
&#xD;
          -  Lesion must be accessible for biopsy&#xD;
&#xD;
          -  History of previously treated CNS metastasis allowed if:&#xD;
&#xD;
               -  Neurologically stable&#xD;
&#xD;
               -  No requirement for IV or oral steroids or IV anticonvulsants&#xD;
&#xD;
               -  No active or residual disease by brain CT or MRI scan&#xD;
&#xD;
          -  Patients with neurologic signs or symptoms suggestive of CNS metastasis must have a&#xD;
             negative brain CT or MRI scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance status: WHO 0-2&#xD;
&#xD;
          -  Life expectancy: At least 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No uncompensated coronary artery disease on electrocardiogram or physical examination&#xD;
&#xD;
          -  No history of myocardial infarction or severe/unstable angina within the past 6 months&#xD;
&#xD;
          -  No severe peripheral vascular disease associated with diabetes mellitus&#xD;
&#xD;
          -  No deep vein or arterial thrombosis within the past 3 months&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 months&#xD;
&#xD;
          -  No significant uncontrolled underlying medical or psychiatric illness&#xD;
&#xD;
          -  No serious active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active second malignancy except nonmelanomatous skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  Patients are not considered to have active malignancy if they have completed therapy&#xD;
             and are considered to be at less than 30% risk of relapse&#xD;
&#xD;
          -  No history of severe allergic or anaphylactic reactions to paclitaxel or docetaxel&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than 1 prior systemic chemotherapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior systemic chemotherapy and recovered&#xD;
&#xD;
          -  Prior intrapleural cytotoxic agents (including bleomycin) allowed&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior investigational drug and recovered&#xD;
&#xD;
          -  No concurrent investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedy L. Kindler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis A. Weiss Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Central Illinois, S.C.</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Health Care</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology/Oncology</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology/Hematology Associates of Central Illinois, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Illinois Hematology Oncology Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46885-5099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology/Oncology P.C.</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>February 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2004</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>epithelial mesothelioma</keyword>
  <keyword>sarcomatous mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Semaxinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

